Forecast

The analysts' average price target is +2,40€ (+328,57%). The median is +2,40€ (+328,57%).

Buy	8
Hold	6
Sell	0

News Go to news feed

Outlook Therapeutics stock jumps 50% after FDA grants its appeal

The FDA granted Outlook Therapeutics’ appeal, finding that there is substantial evidence of effectiveness for LYTENAVA (bevacizumab-vikg) in neovascular age-related macular degeneration. The company plans to refile the Biologics License Application in June 2026; this will be a class 1 re-submission with an expected PDUFA target date to be set within 60 days of receipt. If approved, ONS-5010/LYTENAVA would be the first FDA-approved ophthalmic bevacizumab formulation with an approved manufacturing process, labeling and pharmacovigilance program. » More on de.investing.com
Outlook Therapeutics raises $5.0 million through registered direct offering

Outlook Therapeutics sold 16,129,033 common shares at $0.31 each, raising approximately $5.0 million gross before fees. At the same time, unregistered warrants for up to 16,129,033 shares with an exercise price of $0.31 were issued; upon shareholder approval their exercise could generate up to an additional $5.0 million in gross proceeds. The company also reduced the exercise price of certain outstanding warrants for up to 2,142,854 shares from $2.26 to $0.31. Net proceeds are expected to be used primarily for working capital and general corporate purposes; Outlook Therapeutics is focused on the development and commercialization of bevacizumab for retinal diseases. » More on de.investing.com
Outlook Therapeutics sells 16.13 million shares in direct offering, raises about $5.0 million

Outlook Therapeutics has agreed to sell 16,129,033 common shares or prepaid warrants at $0.31 each in a registered direct offering and expects gross proceeds of approximately $5.0 million before fees. At the same time, unregistered warrants are being issued that entitle holders to purchase the same number of shares at $0.31 and will be exercisable following shareholder approval, which if fully exercised could generate an additional $5.0 million. The exercise price of certain previously issued warrants is being reduced to $0.31. Net proceeds are intended for working capital and general corporate purposes; H.C. Wainwright & Co. is acting as placement agent, and the stock trades around $0.32 with a market capitalization of $33.41 million. » More on de.investing.com

Financials

In the last quarter, Outlook Therapeutics had revenue of 7.89k€ and net profit of −17.80m€

(EUR)	Jun 2026	YoY
Revenue	+7.89k	99,38%
Gross profit	−7.01k	100,78%
Net profit	−17.80m	4,13%
EBITDA	−17.77m	4,33%

Fundamentals

Metric	Value
Market capitalization	+108.70m€
Number of shares	187.00m
52-week high/low	+2,91€ - +0,14€
Dividends	No
Beta	0,8
P/E ratio	−0,36
PEG ratio	0,00
P/B ratio	−1,66
P/S ratio	−108,90

Company profile

Outlook Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im späten klinischen Stadium, das sich auf die Entwicklung und Vermarktung von monoklonalen Antikörpern für verschiedene ophthalmologische Indikationen konzentriert. Der führende Produktkandidat ist ONS-5010, eine ophthalmische Formulierung des Bevacizumab-Produktkandidaten, der sich in einer klinischen Phase-III-Studie für die Behandlung der feuchten altersbedingten Makuladegeneration und anderer Netzhauterkrankungen befindet. Outlook Therapeutics, Inc. hat Kooperations- und Lizenzvereinbarungen mit IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd. und Zhejiang Huahai Pharmaceutical Co. Ltd. Das Unternehmen war früher als Oncobiologics, Inc. bekannt und änderte im November 2018 seinen Namen in Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. wurde im Jahr 2010 gegründet und hat seinen Sitz in Iselin, New Jersey.

Name	Outlook Therapeutics
CEO	Robert Charles Jahr
Headquarters	Iselin, nj USA
Website	outlooktherapeutics.com
Sector	Health Care
Industry	Biotechnology
IPO	06/14/2016
Employees	17